Background:
Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab, sold under the trade name Soliris, binds to binds to terminal complement component 5 (C5), which acts at a late stage in the complement cascade. C5 is part of activation of host cells, helping attract pro inflammatory immune cells. Inhibition of the complement cascade by inhibition of C5 cleavage, impeding inflammation and cell destruction.When activated, C5 is involved in activating host cells, thereby attracting pro-inflammatory immune cells, while also destroying cells by triggering pore formation. By inhibiting the complement cascade at this point, the normal, disease-preventing functions of proximal complement system are largely preserved, while the properties of C5 that promote inflammation and cell destruction are impeded. C5b, which then forms the terminal complement complex C5b-9 also has prothrombotic and proinflammatory effects.
Intended Use:
For Estimation of Eculizumab (SOLIRIS) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
